



"When you can't breathe...nothing else matters"™

ALTG Members' Meeting

17th August 2016

President's Report
ALTG Members' Meeting
17th August 2016



Management Advisory Committee (MAC)



- President Paul Mitchell
- Past-President/Secretary Michael Millward
- SAC Chair Nick Pavlakis
- Treasurer Cameron Hunter
- Allied Health/Nursing Beth Ivimey
- Thoracic Surgery Vacant
- Medical Oncology Craig Lewis
- NZ Member Vacant
- Palliative Care Guy Bannink
- Radiation Oncology Shankar Siva
- Respiratory Medicine Emily Stone



"When you can't breathe...nothing else matters"™

2015 in review – a year of growth



- Membership – Michael Millward
- Finances – Ros Wilson (for Cameron Hunter)
- Trials – Nick Pavlakis

- Strategy review
- Communications
 - Newsletter
- Workshops and educational initiatives
 - Idea generation workshops → member meetings
 - Preceptorship in Lung Cancer
 - Lung Cancer Symposium
- TACT



*"When you can't breathe...nothing else matters"*TM

MISSION

To reduce the incidence, morbidity and mortality of lung and other thoracic cancers and improve the quality of life of patients, their carers and families in Australia and New Zealand by coordinating and facilitating high quality clinical research

OBJECTIVES

Develop and conduct high quality, clinically relevant investigator-led clinical trials

Translate research findings into clinical practice

Ensure the ALTG is a sustainable organisation

INITIATIVES

Collaborate with international groups

Translational research forum

Funding strategy

Lead TACT

ALTG publications

Strengthen ALTG profile and awareness

Develop interest-based subgroups

Annual Scientific Meeting

Maintain and build a broad membership

Maintain current awareness of scientific developments including translational research

Educational activities and workshops

Identify and develop new trial opportunities

Support members to attend educational events

Engage advanced trainees and fellows

Ensure clear and efficient decision-making structures and processes

The ALTG Consumer Advisory Panel will bridge between the world of the consumer and the world of research, by representing the perspective and needs of consumers in the ALTG's initiatives and by improving understanding of the ALTG's activities among consumers

How are we doing against our objectives?



Develop and conduct high quality, clinically relevant investigator-led clinical trials

- Collaborate with international groups
- Lead TACT
- Maintain current awareness of scientific developments including translational research
- Develop interest-based subgroups
- Lead large scale international trial
- Identify and develop new trial opportunities
- Engage advanced trainees and fellows
- Ensure clear and efficient decision-making structures and processes

Translate research findings into clinical practice

- Translational research forum
- ALTG publications
- Annual scientific meeting
- Educational activities and workshops
- Support members to attend educational events

Ensure the ALTG is a sustainable organisation

- Funding strategy
- Strengthen ALTG profile and awareness
- Maintain and build a broad membership

Achieved
Partly achieved
Not achieved



*"When you can't breathe...nothing else matters"*TM

Communications



- **Newsletter**
 - Electronic format since July 2015
 - 35-40% “open rate” (≈580 recipients)
 - Most popular articles (≥ 10)
 - Preceptorship report
 - Committee news (SAC structure)
 - President’s Message
 - Lung cancer research news
 - Research awards and scholarships
 - Who’s Who on the...
 - Member meeting dates



“When you can’t breathe...nothing else matters”™

Workshops and educational initiatives



- Idea generation workshops → member meetings
 - Successful way to generate initial ideas that have been developed into concepts and full trials
 - Bi-annual member meetings
 - Idea generation
 - Trial concept development
 - Scientific/CPD



"When you can't breathe...nothing else matters"™

1st ALTG Preceptorship in Lung Cancer



- 17-18th April 2015, Sydney
- Convenors, Organising Committee and Preceptors
 - Eva Segelov
 - Yada Kanjanapan
 - Karen Lather (LFA)

 - Prunella Blinman
 - Stephen Clarke
 - Chris Karapetis
 - Michael Millward
 - Nick Pavlakis
 - Shane White
- 49 participants
 - Majority medical oncology
 - 40% consultants
 - 60% trainees
- Sponsors
 - Major – Roche
 - Minor – Novartis



*"When you can't breathe...nothing else matters"*TM

2nd ALTG Preceptorship in Lung Cancer



- 28-29th October, Sydney
- Convenors, Organising Committee and Preceptors
 - Nick Pavlakis
 - Eva Segelov
 - Peey Sei Kok
 - Amelia Parsons (LFA)

 - Prunella Blinman
 - Stephen Clarke
 - Tom John
 - Chris Karapetis
 - Michael Millward
- 43 participants
 - Majority medical oncology
 - > 80% trainees
- Sponsors
 - Bristol-Myers Squibb
 - Boehringer Ingelheim
 - MSD
 - Pfizer
 - Roche



*"When you can't breathe...nothing else matters"*TM



SAVE THE DATE

Friday 11th & Saturday 12th November 2016
Hilton Hotel, Sydney

- Further details post-ALCC



*"When you can't breathe...nothing else matters"*TM

The TACT mission

- An international non-profit umbrella organisation for academic research groups from around the world, dedicated to facilitating thoracic oncology research
 - Established 6 September 2015 at Denver WCLC
 - Board: Australia, Hong Kong, USA, Canada, UK, France, Spain, ETOP
 - Legal entity: Lung Foundation Australia
 - Secretariat: Brisbane, QLD Australia
 - Dr Ros Wilson – Research Development Officer



Aims

- Facilitate and promote international research collaboration in thoracic cancer
- Provide a platform to conduct clinical trials requiring multiple groups
- Combine resources and expertise to conduct research more efficiently and reduce duplication of effort
- Allow trials to recruit more quickly
- Establish clinical and translational research priorities



Operating principles

- Mutual respect and equity for individuals, cultures and nations
- A strong sense of common purpose
- Providing new opportunities for all members; not replicating an existing group
- Facilitating, supporting and serving as a mechanism to advance the intellectual contributions of individuals and member groups
- Independence from the pharmaceutical/ biotechnology industry, even if trials are industry-sponsored
- Adherence to Good Clinical Practice guidelines and applicable laws
- An agreed set of rules to support fair and efficient processes within the group



Activities

- Build on existing international relationships
- Develop and conduct trials which require large numbers of patients and/or where accrual is difficult
 - Including multi-modality therapy and rare thoracic malignancies or subtypes
- Conduct translational research
- Collaborate with other scientific networks
- Develop models of collaboration with the pharmaceutical and biotechnology industry that preserve scientific independence
- Promote other academic thoracic oncology activities



Member Groups



Industry Partners



Bristol-Myers Squibb

AstraZeneca 

The AstraZeneca logo features the word "AstraZeneca" in a purple, sans-serif font. To the right of the text is a yellow, stylized logo icon consisting of two interlocking, curved shapes that form a diamond-like pattern.

Initiatives

- Ongoing discussions with other international cancer trials groups
 - BIG (Breast International Group)
 - GCIG (Gynecologic Cancer InterGroup)
- Meetings with global pharmaceutical companies
 - Information about TACT
 - Trial opportunities
 - Knowledge about running global trials
 - Build partnerships
- TACT policies and procedures
- Trial proposal procedures
 - Proposal sent to secretariat
 - Discussed by board (disease sub-committees)
 - Put to General Assembly
- An early focus on operational harmonisation – GCP, indemnity, consent, documentation, databases, data collection, data analysis
- Interaction & dialogue with other international lung cancer groups
 - IASLC
 - Lung Cancer Nurses Group (ITONF)



Thoracic Alliance for Cancer Trials

TACT is an international non-profit collaboration of groups dedicated to thoracic oncology clinical research. Our worldwide network helps researchers navigate an increasingly complex landscape as understanding of lung cancer and new treatment approaches evolve.

[LEARN MORE](#)



Welcome

Enquiries

Welcome to the website of TACT, the Thoracic Alliance for Cancer Trials. TACT is a unique opportunity to improve outcomes for patients with thoracic malignancy by facilitating clinical research through a truly global network, harmonisation of governance and operations and fostering a genuine collaboration among groups and with external partners. TACT was established in September 2015 at the 16th World Conference on Lung Cancer in Denver, Colorado as an international non-profit umbrella organisation for worldwide academic groups who are dedicated to thoracic oncology research. With our global reach, TACT is ideally positioned to navigate the increasingly complex landscape of lung cancer diagnosis and novel treatment approaches by enabling lung cancer researchers worldwide to work together on joint projects and clinical trials.

Paul Mitchell, Board Chair

TACT Development Officer
c/o Lung Foundation Australia

PO Box 1949
Milton QLD 4064
Australia

T: +61 (0) 7 3251 3600
M: +61 (0) 481 394 982
F: +61 (0) 7 3368 3564
E: enquiries@tactlung.com